Information Regarding SARS-CoV-2 Strains and Reagents

FAQs 

Materials Available

Coming Soon

Forms
 

BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations and orders.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations and a 24-48 hour turn-around time on approved orders.  Please indicate SARS-CoV-2 in your scope of use in your registration paperwork.  Please contact BEI Resources at contact@beiresources.org for questions.

BEI Resources is working to accession strains of the 2019 novel coronavirus, recently named SARS-CoV-2, identified as the causative agent of an outbreak of viral pneumonia, COVID-19. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

  

Currently Available SARS-CoV-2 Materials

 Item Number   Description  Registration Level  
 Virus
 NR-52281  SARS-CoV-2, Isolate USA-WA1/2020  BEI Level 3
 NR-52282  SARS-CoV-2, Isolate Hong Kong/VM20001061/2020  BEI Level 3
 NR-52284  SARS-CoV-2, Isolate Italy-INMI1  BEI Level 3
 NR-52359  SARS-CoV-2, Isolate England/02/2020  BEI Level 3
 NR-52369  SARS-CoV-2, Isolate Singapore/2/2020  BEI Level 3
 NR-52370  SARS-CoV-2, Isolate Germany/BavPat1/2020  BEI Level 3
 NR-52381  SARS-CoV-2, Isolate USA-IL1/2020  BEI Level 3
 NR-52382  SARS-CoV-2, Isolate USA-CA1/2020  BEI Level 3
 NR-52383  SARS-CoV-2, Isolate USA-AZ1/2020  BEI Level 3
 NR-52384  SARS-CoV-2, Isolate USA-WI1/2020  BEI Level 3
 NR-52385  SARS-CoV-2, Isolate USA-CA3/2020  BEI Level 3
 NR-52386  SARS-CoV-2, Isolate USA-CA4/2020  BEI Level 3
 NR-52387  SARS-CoV-2, Isolate USA-CA2/2020  BEI Level 3
 NR-52439  SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020  BEI Level 3
 NR-53514  SARS-CoV-2, Isolate New York-PV08410/2020  BEI Level 3
 NR-53515  SARS-CoV-2, Isolate New York-PV08449/2020  BEI Level 3
 NR-53516  SARS-CoV-2, Isolate New York-PV09158/2020  BEI Level 3
 NR-52390  Adenovirus Serotype 5, Clone Ad5-CMV-hACE2/RSV-eGFP, Recombinant Expressing Human ACE2  BEI Level 2
 Nucleic Acid
 NR-52285  Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020  BEI Level 2
 NR-52388  Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020  BEI Level 2
 NR-52498  Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1  BEI Level 2
 NR-52358  Quantitative Synthetic RNA from SARS-CoV-2  BEI Level 1
 NR-52346  Quantitative PCR (qPCR) Control RNA from Inactivated SARS Coronavirus, Urbani  BEI Level 1
 NR-52347  Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020  BEI Level 1
 Inactivated Organisms
 NR-52286  SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated   BEI Level 1
 NR-52287  SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated   BEI Level 1
 NR-52349  Quantitative PCR (qPCR) Extraction Control from Inactivated SARS Coronavirus, Urbani   BEI Level 1
 NR-52350  Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020   BEI Level 1
 Cell Line
 NR-52511  Human Embryonic Kidney Cells (HEK-293T) Expressing Human Angiotensin-Converting Enzyme 2, HEK-293T-hACE2 Cell Line   BEI Level 2
 Monoclonal Antibody
 NR-52392  Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana  BEI Level 1
 Serum/Plasma
 NR-53593 - NR-53692   SARS-CoV-2, Human Plasma and PBMC Samples  BEI Level 2
 NR-53736  SARS-CoV-2, Human Peripheral Blood Mononuclear Cells (PBMC), Subject ID: LPEQAP142  BEI Level 2
 NR-53737  SARS-CoV-2, Human Plasma, Subject ID: LPEQAP142  BEI Level 2
 NR-53738  SARS-CoV-2, Human Serum, Subject ID: 0873-294  BEI Level 2
 NR-52401  Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated   BEI Level 2
 Protein
 NR-52307  Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1, Recombinant from Baculovirus  BEI Level 1
 NR-52366  Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1, Recombinant from HEK293 Cells (This item replaces NR-52306)  BEI Level 1
 NR-52397  Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293F Cells  BEI Level 1
 NR-52946  Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293T Cells  BEI Level 1
 NR-53246  Nucleocapsid Protein N-Terminal RNA Binding Domain from SARS-CoV-2, Wuhan-Hu-1 with N-Terminal Histidine Tag, Recombinant from E. coli   BEI Level 1
 NR-53257  Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells    BEI Level 1
 NR-53524  Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Avi Tags, Recombinant from HEK293F Cells   BEI Level 1
 Peptide Array
 NR-52402  Peptide Array, SARS-CoV-2 Spike (S) Glycoprotein   BEI Level 1
 NR-52403  Peptide Array, SARS-CoV-2 Membrane (M) Protein   BEI Level 1
 NR-52404  Peptide Array, SARS-CoV-2 Nucleocapsid (N) Protein   BEI Level 1
 NR-52405  Peptide Array, SARS-CoV-2 Envelope (E) Protein   BEI Level 1
 Plasmid
 NR-52948  SARS-CoV-2, Wuhan-Hu-1 Spike-Pseudotyped Lentiviral Kit    BEI Level 1
 NR-53260  Plasmid Set for Anti-SARS Coronavirus Human Monoclonal Antibody CR3022    BEI Level 1
 NR-52309  Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene RBD with C-Terminal Hexa-Histidine Tag   BEI Level 1
 NR-52310  Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene   BEI Level 1
 NR-52394  Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene (soluble, stabilized)   BEI Level 1
 NR-52420  Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene   BEI Level 1
 NR-52421  Vector pCMV Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain   BEI Level 1
 NR-52422  Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD   BEI Level 1
 NR-52423  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 SARS-CoV Unique Domain Gene   BEI Level 1
 NR-52424  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 9 Gene    BEI Level 1
 NR-52425  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 10 Gene   BEI Level 1
 NR-52426  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 15 Gene   BEI Level 1
 NR-52427  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 16 Gene   BEI Level 1
 NR-52428  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein N-Terminal Domain   BEI Level 1
 NR-52429  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein RNA Binding Domain Gene   BEI Level 1
 NR-52430  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD   BEI Level 1
 NR-52431  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1
 NR-52432  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   BEI Level 1
 NR-52433  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 14 Gene   BEI Level 1
 NR-52434  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein C-Terminal Domain Gene   BEI Level 1
 NR-52435  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 4 Gene, Cytoplasmic C-Terminal Domain   BEI Level 1
 NR-52512  Vector pHAGE2 Containing the Angiotensin-Converting Enzyme 2 Gene   BEI Level 1
 NR-52513  Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant, HA Tag   BEI Level 1
 NR-52515  Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant ALAYT   BEI Level 1
 NR-52520  Vector pHAGE2 Containing the ZsGreen Gene   BEI Level 1
 NR-52563  Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain   BEI Level 1
 NR-52564  Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein   BEI Level 1
 NR-52565  Modified pαH Vector Containing the Human Angiotensin-Converting Enzyme 2   BEI Level 1

 

We anticipate a large number of requests from the research community for these reagents, and we cannot guarantee how quickly stock will become available. Please continue checking for updates.

If you wish to transfer SARS-CoV-2 materials, please use the guidance provided in the Emergency Use Simple Letter Agreement.

  

Coming Soon and Expected Availability

 Item Number   Description  Expected Availability 
 Virus
 NR-52368  SARS-CoV-2, Isolate New York-PV08001/2020  Late July
 NR-53517  SARS-CoV-2, Isolate New York-PV09197/2020  Late July
 Nucleic Acid
 NR-52389  Genomic RNA from SARS-CoV-2, Isolate New York-PV08001/2020  August
 NR-52499  Genomic RNA from SARS-CoV-2, Isolate England/02/2020  Mid July
 NR-52502  Genomic RNA from SARS-CoV-2, Isolate Germany/BavPat1/2020  Late July
 NR-52503  Genomic RNA from SARS-CoV-2, Isolate USA-IL1/2020  Mid July
 NR-52504  Genomic RNA from SARS-CoV-2, Isolate USA-CA1/2020  Mid July
 NR-52505  Genomic RNA from SARS-CoV-2, Isolate USA-AZ1/2020  July
 NR-52506  Genomic RNA from SARS-CoV-2, Isolate USA-WI1/2020  Mid July
 NR-52507  Genomic RNA from SARS-CoV-2, Isolate USA-CA3/2020  July
 NR-52508  Genomic RNA from SARS-CoV-2, Isolate USA-CA4/2020  Late July
 NR-52509  Genomic RNA from SARS-CoV-2, Isolate USA-CA2/2020  Late July
 Cell Line
 NR-53522  A549 cells expressing human ACE2 (HA-FLAG)   July
 Protein
 NR-52308  Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1, Recombinant from Baculovirus (This item replaces NR-52396)   Mid July
 NR-52348  Spike Glycoprotein from SARS-CoV-2, Wuhan-Hu-1, Recombinant from HEK293T Cells   July
 NR-52724  Recombinant Spike, SARS-CoV-2 Stabilized Protein   Late July
 Peptide Array
 NR-52418  Peptide Array SARS-CoV S Protein (Peptides 1 to 169)   August 
 NR-52419  Peptide Array SARS-CoV N Protein (Peptides 1 to 57)   August
 Plasmid
 NR-52436  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Papain-Like Protease Gene   July 
 NR-52437  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 3C-Like Protease Gene   July
 NR-52438  Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 3 ADP-Ribose-1"-Phosphatase Domain   July
 NR-52897  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Papain-Like Protease Gene   July 
 NR-52898  Vector pCSGID Containing the SARS-CoV-2, Wuhan-Hu-1 3C-Like Protease Gene   July
 NR-52899  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 1 Gene   July
 NR-52900  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   July
 NR-52901  Vector pMCSG120 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   July
 NR-52902  Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   July

 

The BEI Resources catalog offers additional coronavirus materials ready and available for distribution to qualified laboratories.

For access to BEI Resources full catalog, click here.

 

Frequently Asked Questions 

  1. Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?
  2. How long will it take to get SARS-CoV-2 materials?
  3. How long will it take to process my registration to receive SARS-CoV-2 materials?
  4. Who is qualified to receive SARS-CoV-2 materials?
  5. What level of registration do I need to receive SARS-CoV-2 materials?
  6. If I have questions regarding SARS-CoV-2 materials, who do I contact?
  7. How much do SARS-CoV-2 materials cost?
  8. What is the Emergency Use Simple Letter Agreement (EUSLA)?
  9. Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?
  10. Can I transfer SARS-CoV-2 materials?
  11. Can I commercialize SARS COV-2 materials?
  12. Are COVID-19 patient samples currently available from BEI Resources?
  13. How do I obtain test kits for COVID-19?
  14. Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?
  15. Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates?
  16. Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?
  17. How do I find out about SARS-CoV-2 products coming soon?

 

Question: Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?

Answer: No, BEI Resources currently does not have a shortage or a delay in shipping virus and RNA to qualified laboratories. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

Back to Questions

 

Question: How long will it take to get SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing all SARS-CoV-2 shipments.  Shipments are generally being made within 24-48 hours of completed requests.  If permits are required, these timelines are dependent on obtaining those permits.  Please contact us at contact@beiresources.org for any shipment questions.

Back to Questions

 

Question: How long will it take to process my registration to receive SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations.  Please indicate SARS-CoV-2 in your scope of use.  Please contact BEI Resources at contact@beiresources.org for questions.

Back to Questions

 

Question: Who is qualified to receive SARS-CoV-2 materials?

Answer: Registration with BEI Resources is required to request SARS-CoV-2 materials. BEI Resources reagents are shared with registered individuals and organizations doing research on Emerging Infections and other relevant areas of interest related to Microbiology. To register you must be affiliated with a public, private, academic, non-profit or for-profit institution. Registrants must demonstrate they work in an established institution with facilities and safety programs appropriate for the Level of registration requested.

Back to Questions

 

Question: What level of registration do I need to receive SARS-CoV-2 materials?

Answer: Each product on the BEI Resources website lists a BEI Resources level of registration.  Interested researchers will need to ensure they are registered at the appropriate level to receive materials.  Please click here for registration instructions.  If you need to upgrade your registration to a higher level, please click here for instructions.

Back to Questions

 

Question: If I have questions regarding SARS-CoV-2 materials, who do I contact?

Answer: Please contact BEI Resources at contact@beiresources.org for any questions regarding SARS-CoV-2 materials.

Back to Questions

 

Question: How much do SARS-CoV-2 materials cost?

Answer: All BEI Resources reagents, including SARS-CoV-2 materials, are provided world-wide at no cost. While there is no cost for the reagents themselves, additional shipping and handling charges may apply and will display in the shopping cart if applicable.

Back to Questions

 

Question: What is the Emergency Use Simple Letter Agreement (EUSLA)?

Answer: The Emergency Use Simple Letter Agreement outlines the terms in which SARS-CoV-2 materials are being provided.  In light of the emergence of the novel coronavirus, 2019-SARS-CoV-2, and urgent need to mitigate the pathogen’s spread, the EUSLA was instituted for the provision of these materials under the terms outlined in the agreement. The EUSLA is not negotiable.

Back to Questions

 

Question: Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?

Answer: The viruses, nucleic acids, and inactivated SARS-CoV-2 organisms, along with the gamma irradiated NHP convalescent serum from SARS-CoV-2, are distributed under the terms of the EUSLA. Please note that the signature of the biosafety officer to certify that your facility can safely handle the material is required for receipt of the virus. The following is a list of items distributed by BEI under the EUSLA:

 

 Item Number   Description
 NR-52281  SARS-CoV-2, Isolate USA-WA1/2020
 NR-52282  SARS-CoV-2, Isolate Hong Kong/VM20001061/2020
 NR-52284  SARS-CoV-2, Isolate Italy-INMI1
 NR-52359  SARS-CoV-2, Isolate England/02/2020
 NR-52369  SARS-CoV-2, Isolate Singapore/2/2020
 NR-52370  SARS-CoV-2, Isolate Germany/BavPat1/2020
 NR-52381  SARS-CoV-2, Isolate USA-IL1/2020
 NR-52382  SARS-CoV-2, Isolate USA-CA1/2020
 NR-52383  SARS-CoV-2, Isolate USA-AZ1/2020
 NR-52384  SARS-CoV-2, Isolate USA-WI1/2020
 NR-52385  SARS-CoV-2, Isolate USA-CA3/2020
 NR-52386  SARS-CoV-2, Isolate USA-CA4/2020
 NR-52387  SARS-CoV-2, Isolate USA-CA2/2020
 NR-52439  SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020
 NR-53514  SARS-CoV-2, Isolate New York-PV08410/2020
 NR-53515  SARS-CoV-2, Isolate New York-PV08449/2020
 NR-53516  SARS-CoV-2, Isolate New York-PV09158/2020
 NR-52285  Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020
 NR-52388  Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020
 NR-52498  Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1
 NR-52347  Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020
 NR-52286  SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated 
 NR-52287  SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated 
 NR-52350  Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020 
 NR-52401  Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated 
 NR-53593 - NR-53692   SARS-CoV-2, Human Plasma and PBMC Samples
 NR-53736  SARS-CoV-2, Human Peripheral Blood Mononuclear Cells (PBMC), Subject ID: LPEQAP142
 NR-53737  SARS-CoV-2, Human Plasma, Subject ID: LPEQAP142
 NR-53738  SARS-CoV-2, Human Serum, Subject ID: 0873-294

 

Back to Questions

 

Question: Can I transfer SARS-CoV-2 materials?

Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA may be further distributed to other entities for legitimate purposes required to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of SARS-CoV-2 and under terms no more restrictive than the Emergency Use Simple Letter Agreement (EUSLA). To ensure compliance with this, copies of the EUSLA or MTAs recording all further transfers must be sent back to contact@beiresources.org. This requirement must also be incorporated for further transfers. The recipient and provider agree to transfer, use, manage, and control the SARS-CoV-2 materials in compliance with all applicable laws and regulations. When these commodities, technology or software are exported from the United States, the recipient agrees to comply with the Export Administration Regulations. Diversion contrary to U.S. law is prohibited.

Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.

Back to Questions

 

Question: Can I commercialize SARS COV-2 materials? 

Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA are made available for any legitimate purpose, including commercial purposes, as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA (see question above regarding transfer of SARS-CoV-2 materials). Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.

Back to Questions

 

Question: Are COVID-19 patient samples currently available from BEI Resources?

Answer: We understand how important it is to share patient samples, including sera, nasal swabs and PBMCs, with researchers, especially during an outbreak. We will have a very limited number of samples available. Requestors must limit their orders to 5 pairs of matched serum/plasma and PBMCs OR 5 samples of serum/plasma. We anticipate a large number of requests from the research community for patient samples related to the pandemic, and will continually work towards making more samples available. Please order according to the limits above and contact our email box at contact@beiresources.org with any questions. If we are not able to fill your needs, please contact us so we can forward your request to NIAID to prioritize those samples once available.

Back to Questions

 

Question: How do I obtain test kits for COVID-19?

Answer: Test kits are not distributed through BEI Resources. The CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel was developed for qualified domestic public health laboratories to detect SARS-CoV-2. The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on February 4, 2020, to enable emergency use of the test kit in the United States. CDC has produced EUA and Research Use Only (RUO) test kits that are now available to order by domestic and international public health partners through IRR (www.internationalreagentresource.org). Please contact the International Reagent Resources program for more information – contact@internationalreagentresource.org.

Back to Questions

 

Question: Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?

Answer: CDC guidelines state that molecular analysis of extracted nucleic acid preparations should be performed in BSL-2 facility using standard BSL-2 work practices. The CDC guidelines can be found in the following link: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html

Back to Questions

 

Question: Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates

Answer: The BEI Resources website provides a link on each product detail page for applicable permits. Please check the individual product detail pages for this information. SARS-CoV-2 isolates which originate from the United States do not require a CDC permit for domestic transfer. SARS-CoV-2 isolates which are deposited into BEI Resources outside of the USA, will be brought into the repository under a CDC permit, and will require a CDC permit for transfer.

Back to Questions 

 

Question: Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?

Answer: All Product Sheets and Certificates of Analysis can be found on the BEI Resources website. Perform a search for the product, and you will find the documentation. Any product listed as requiring a BSL-3 facility, will require login first to view the documentation. Only BEI Level 3 registrants will have access to view and download products requiring BSL-3 facilities.

Back to Questions 

 

Question: How do I find out about SARS-CoV-2 products coming soon?

Answer: BEI Resources will list the status of SARS-CoV-2 products coming soon in the table above titled Coming Soon and Expected Availability.

Back to Questions 

 

Forms

Emergency Use Simple Letter Agreement (EUSLA)

 

Back to the top

View More Highlights